丹参注射液对慢性阻塞性肺疾病急性加重期细胞间黏附分子-1表达的影响

The Effects of Slavia Miltiorrhiza Injection on the Expression of sICAM-1 of Patients with COPD

目的:研究外周血血清可溶性细胞间黏附分子-1(sICAM-1)与慢性阻塞性肺疾病(COPD)发病的关系、丹参注射液对sICAM-1表达及肺功能的影响。方法:采用ELISA酶联免疫吸附法测定40例COPD急性加重期患者(COPD组),分为COPD组1和COPD组2各20例,给予常规抗感染、解痉、平喘及吸氧等西医综合治疗,COPD组2加用丹参注射液20 ml及50%葡萄糖500 ml静脉滴注,每日1次。另设20例健康者为对照组。治疗前后分别检测血清sICAM-1的表达及其相应的肺功能(FEV1%)。结果:COPD组患者血清sICAM-1水平明显高于对照组,FEV1%显著低于对照组(均P<0.01)。治疗10 d后,COPD组与治疗前比较,血清sICAM-1明显下降(P<0.05,0.01)。COPD组2血清sICAM-1水平低于COPD组1,FEV1%高于COPD组1(P<0.05)。COPD组血清sICAM-1与FEV1%呈显著负相关。结论:血清sICAM-1参与COPD的发病,丹参能明显阻抑外周血血清sICAM-1的表达,这可能是此类中药具有抗炎活性的又一机理。

Objective： To investigate the relationship between the expression of sICAM-1 and the pathogenesis of COPD and the effects of Slavia miltiorrhiza injection on the expression of sICAM-1 and FEVI% of patients with COPD. Methods： Forty COPD patients at acute exacerbation phase were divided into conventional treatment group, and Slavia miltiorrhiza-treated group, and 20 normal healthy subjects served as control group. By means of enzyme linked immunosorbent assay （ELISA）, the levels of the sICAM-1 expression was detected, and FEV1% was measured. Results： （1） T.he expression level of sICAM-1 in patients with COPD at acute exacerbation was significantly higher, but the FEV1% lower than in control group （both P〈0. 01）; （2） After treatment for 10 days, the sICAMq expression levels were significantly reduced in COPD group as compared with those before treatment （P〈0.05）. The expression of sICAM-1 was significantly decreased, while FEV1% increased in Slavia miltiorrhiza-treated group as compared with conventional treatment group （P〈0.05）. （3） In COPD groups, the expression of sICAM-1 and FEV1% had an negative correlation. Conclusion： sICAM-1 may play a central role in the pathogenesis of COPD. Slavia milt- iorrhiza injection can obviously inhibit the expression of sICAM-1.